Physician
Hematology
Dr. Rafat H. Ansari, MD
|
|
Give Review
Rafat Ansari practices Hematology. He researched medicine at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45 in research and 47 in primary care medicine Dr. Rafat H. Ansari is a published doctor. He published 14 publications, including: 'Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
- Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung Cancer,...
- Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung Cancer treated with cisplatin, etoposide, and concurrent chest radiation w...
- Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe.
- Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung Cancer.
- The epothilone B analogue ixabepilone in patients with advanced hepatobiliary Cancers: a trial of the University of Chicago Phase II Consortium.
- Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced Carcinoma of the esophagus or gastroesophageal junction.
- Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenoCarcinoma...
- Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung Cancer.
- Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lu...
- Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myelo...
- Phase II trial of PS-341 in patients with renal cell Cancer: a University of Chicago phase II consortium study.
- Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy ...
Schools
Liaquat Medical College
Clarian Indiana University Hospital
Louis a Weiss Mem Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
Indiana University School of Medicine -
Liaquat Medical College Sind
Drug Facts
| NPI NUMBER | 1013911593 | |
| NPPES Provider LastName | ANSARI | |
| NPPES Provider FirstName | RAFAT | |
| NPPES Provider ZIPCode | 466011033 | |
| NPPES Provider State | IN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 2292.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 197.0 | |
| Percent Opioid Claims | 8.6 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013911593 |
| Last Name Of The Provider | ANSARI |
| First Name Of The Provider | RAFAT |
| View All |
Similar Doctors
|
|
Dr. Richard C. Buck, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Taber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald H. Kawauchi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean Park, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas A. Troeger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robin T. Zon, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rudolph M. Navari, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Muhammad H. Isa, MD |
|
|
Dr. Lowell D. Smith, MD |